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Abstract
Purpose Metformin has been suggested to possibly reduce cancer risk. However, the mechanism underlying the positive 
effects of metformin on cancer treatment remains unclear. We conducted a prospective study to evaluate the effects of pre-
operative metformin in patients with early breast cancer.
Method We evaluated the effects on immunological factors (TILs, CD4 + , CD8 + , PD-L1, IFNγ and IL-2) by comparing 
core needle biopsies (CNB) obtained before metformin treatment with surgical specimens. Seventeen patients were enrolled 
in this prospective study from January to December 2016. We also analyzed 59 patients undergoing surgery during the same 
period to reveal the correlation of immune factors between CNB and surgical specimen.
Result There was a moderate correlation between CNB and surgical specimens on TILs and CD8 + lymphocyte. (TILs 
Rs = 0.63, CD4 + Rs = 0.224, CD8 + Rs = 0.42) In the metformin group, TILs increases were confirmed in five (29%) patients, 
while a decrease was confirmed in two (12%). The expressions of CD4 + and CD8 + by TILs were increased in 41% and 
18% of surgical specimens, respectively. However, TILs number (p = 0.0554), CD4+ (p = 0.0613) and CD8 + (p = 0.0646) 
expressions did not significantly increased. Furthermore, IFNγ expression appeared to be increased in response to metformin 
(p = 0.08).
Conclusion Preoperative metformin tends to increase TILs, as well as the numbers of CD4 and CD8 positive lymphocytes, 
and IFNγ levels. Metformin might improve immune function and have a possibility of chemo-sensitivity and thereby increase 
the effectiveness of immunotherapy, based on the results of this preliminary study.
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Introduction
Breast cancer is among the major causes of cancer-related 
death in women worldwide. While significant progress has 
been made in the diagnosis and treatment of breast cancer, 
the clinical outcomes of patients are still discouraging [1, 
2]. Diabetes mellitus (DM) has an adverse impact on cancer. 
A systematic review indicated DM patients to have a 17% 
increased risk for breast cancer mortality [3]. One report 
has suggested that treating DM with metformin, that is one 
of the commonly prescribed drugs for type 2 DM, reduces 
the risk of breast cancer death as compared with sulfonylu-
reas and insulin formulations [4]. However, the mechanism 
underlying the favorable effect of metformin on cancer epi-
demiology has yet to be investigated in detail.
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Preclinical research using both breast cancer cell lines 
and mouse models subsequently showed that metformin 
represses cancer cell and xenograft growth. Some of the 
reported mechanisms are that metformin preferentially 
kills cancer stem cells through activation of AMP-activated 
protein kinase, leading to activation of FOXP 3, and the 
inhibition of m-TOR, a crucial signaling pathway for cel-
lular proliferation and the survival of cancer cells, and also 
exerts an anti-tumor effect by enhancing immune function 
[5–7]. Of these mechanisms, the metformin’s effect on tumor 
microenvironment including immune functions is drawing 
attentions. Eikawa et al. showed that an anti-tumor effect of 
metformin is dependent on CD8+ T-cells in a murine model 
[7]. Nicole et al. reported that although tumor hypoxia inhib-
its T-cell function, metformin improves an inhibitor of tumor 
oxygen consumption and increases activation of T-cell [8].
Moreover, it is certain that the interplay between immune 
cells and tumor cells exerts a major influence on both the 
development and the progression of breast cancer [9]. Espe-
cially, the role of the cytotoxic T lymphocytes in tumori-
genesis, has been explored extensively. T-cell infiltration in 
invasive breast cancer has been reported that secrete several 
inflammatory cytokines, for example interferon-γ (IFNγ), 
transforming growth factor beta (TGF-β), tumor necro-
sis factor alpha (TNFα) and interleukin-2 (IL-2). These 
cytokines then interact with other cytotoxic T-cells and 
upregulate the MHC class I and II molecules, as well as 
other antigen display co-factors in neoplastic cells [10]. We 
believe this process is an essential part of immune-mediated 
anti-tumorigenic effects.
The immune factor has an important role in clinical prac-
tice. Tumor infiltrating lymphocytes (TILs) are known to be 
prognostic factors as well as markers predicting chemo-sen-
sitivity [11, 12]. Mao et al. conducted a meta-analysis which 
showed that higher levels of TILs correlated with the pCR 
rate in response to neoadjuvant chemotherapy (NAC) [15]. 
Other reports show that TILs is a significant predictor of the 
pathologic complete response in patients with triple-negative 
(TN) and human epidermal growth factor receptor-2 (HER2) 
positive breast cancer subtypes [13, 14]. In addition, various 
TIL subsets have different roles in breast cancer progres-
sion. CD4 + and CD8 + lymphocytes play crucial parts in 
determining cancer treatment and high intra-tumoral lym-
phocyte counts were found to be associated with better sur-
vival in breast cancer patients [16]. And higher levels of 
CD8 + T-lymphocytes in pre-treatment biopsy specimens 
predicted a better pathological response to NAC [15]. And 
cancer immunotherapy (PD-1, PDL-1 antigen) approaches 
have become among the most effective treatments for meta-
static breast cancer [17].
Thus, we speculate that metformin improves immune 
function and favorably modifies the tumor environment. 
To our knowledge, there are no prior studies examining the 
influences of metformin on TILs, CD4 + , CD8 + , IFNγ, 
IL-2 and PDL-1 in patients without DM. We conducted 
this prospective study to confirm the effects of preoperative 
metformin in patients with early breast cancer (metformin 
study).
Materials and methods
To evaluate the effects of metformin, we decided to do two 
studies. First, we gathered patients who had been diagnosed 
with breast cancer by CNB and after that they took met-
formin in the preoperative period, and we compare CNB 
that was pre-metformin with surgical specimen that was 
post-metformin. (metformin study) Second, because of 
breast cancer is known to have tumor heterogeneities, it is 
not uncertain to compare CNB with surgical specimen on 
immune functions. So, we should analyze the correlations 
of immune functions between CNB and surgical specimens. 
We assessed patients who underwent surgery and did not 
take metformin during the same period. (correlation study).
The patients, who had newly diagnosed stage I or IIA 
breast cancer and no history or evidence of DM based on 
blood biochemistry, were not taking metformin before 
enrollment in this study. All participants were enrolled 
between January and December 2016 at Okayama Univer-
sity Hospital. All participants were then administered a daily 
dose of metformin orally for 2 weeks before surgery. All 
17 patients had the same oral metformin dosing schedule: 
500 mg daily for 3 days (250 mg twice after the morning 
and evening meal), increased to 750 mg daily for next 4 days 
(250 mg three times after every meals), and if no adverse 
effects were observed, the dose was increased to 1000 mg 
daily for next 7 days before surgery (500 mg twice after the 
morning and evening meal).
Patients who received NAC or had recurrent tumors were 
excluded. Hematoxylin–eosin (HE)-stained slides of CNB 
and matched surgical specimens were reviewed retrospec-
tively. We evaluated the expressions of and concordance 
between immuno-histological factors in CNB and surgical 
specimens from the same patient.
All clinical data were retrospectively extracted from our 
institution’s electronic medical records system. Metformin 
study was approved by the Ethics Committee of Okayama 
University Hospital (UMIN 000,014,090) and adhered to 
the Declaration of Helsinki. We obtained consent in writ-
ing from each patient. In addition, correlation study was 
approved by the Ethics Committee of Okayama University 
Hospital and adhered to the Declaration of Helsinki.
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Immunohistochemistry
Tumor morphology was evaluated using conventional HE-
staining. Estrogen receptor (ER)/ progesterone receptor (PR) 
and HER2 were assessed according to standard guidelines. 
Nuclear staining ≧ 1% for estrogen receptors (ER) or pro-
gesterone receptors (PgR) was considered to be positive. 
HER2 positivity was defined as 3 + receptor overexpression 
on immunohistochemical (IHC) staining or gene amplifica-
tion on fluorescence hybridization using a HER2/CEP ratio 
≧ 2.0. The expressions of ER, PgR, HER2 and the Ki67 
labelling index (Ki67) in both CNB and surgical specimens 
were determined.
Prior to IHC staining for immune factors, the tumor speci-
mens were fixed in 10% formaldehyde solution and embed-
ded in paraffin, then sliced into 4-μm-thick sections. We 
employed the Ventana Discovery XT automated platform 
(Ventana Medical Systems: Roche Tissue Diagnostics). Pri-
mary monoclonal antibodies directed against CD4 (SP35 
Rabbit monoclonal antibody; Roche Tissue Diagnostics), 
CD8 (SP57 Rabbit monoclonal antibody; Roche Tissue 
Diagnostics), IFNγ (ab9657 Rabbit anti-interferon gamma 
antibody; Abcam), IL-2 (EPR2780 Rabbit monoclonal anti-
body; Abcam) and PD-L1 (22C3 Mouse monoclonal antihu-
man PD-L1 antibody; Dako North American) were used.
To determine the efficacy of metformin, we evaluated 
TILs, as well as CD4, CD8, IFNγ, IL-2 and PDL-1 expres-
sions, in both CNB and surgical specimens (Fig. 1).
Evaluation of TILs
HE-stained sections were utilized for evaluation for TILs. 
The percentages of stromal lymphocytes, serving as a 
predefined criterion in Denkert’s reports, were evaluated 
by one highly experienced observer [14, 18, 19]. Stromal 
TILs were measured as the percentage of immune cells in 
stromal tissue within the tumor that showed a mononuclear 
immunological infiltrate. Heterogeneous distributions were 
documented in nearly all sections. Therefore, hot spots, 
cold spots, and Tertiary Lymphoid Structure were not taken 
into consideration in conducting the measurements, with 
just one representative area being selected and evaluated. 
We divided the proportions of TILs into 10% increments. 
TILs were categorized according to three cut-off values, as 
a dichotomous variable (0 to 10%: negative, 11–30%: low, 
31–50%: intermediate, over 51%: high). We also decided 
whether there was a 20% difference between the CNB and 
the surgical specimen.
Evaluation of CD4 + and CD8 + T‑lymphocytes, IFNγ, 
IL‑2 and PD‑L1
Based on previous studies, CD4 + and CD8 + expressions 
were calculated using the average of stained TILs in the area 
that was maximally stained, viewed at 400 × magnification 
[20, 21]. We randomly selected two different high-power 
fields and counted those expressing CD4 + or CD8 + in 100 
lymphocytes.
The semi-quantitative H scoring system was employed, 
using whole tissue sections, to evaluate the presence of IFNγ 
and IL-2. The H score was calculated by multiplying the 
percentage of positive cells (tumor and immune) by a factor 
representing the intensity of immune-reactivity (1 for weak, 
2 for moderate, and 3 for strong), giving a maximum score of 
300. A score below 50 was considered negative and a score 
of over 50 was positive.
Fig. 1  The expression of TILs, CD4 + , CD8 + and PD-L1 both CNB and surgical specimens among the same patient. There was increasing of 
TILs, CD4 + and CD8 + lymphocyte. TILs: (A, a), CD4 + : (B, b), CD8 + lymphocytes: (C, c), PD-L1: (D, d)
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PD-L1 expression was categorized as positive when 
staining of the tumor-cell membrane (at any intensity) was 
observed at pre-specified expression levels of 1%, 5%, or 
10% of cells in a section that included at least 100 tumor 
cells that could be evaluated [17]. As judging PD-L1 expres-
sion is difficult, we asked an experienced pathologist to 
determine the expression rates.
Statistical analysis
This study was a non-planned, retrospective, exploratory 
project, for which all available cases were used without a 
predefined sample size calculation to detect a specific effect 
size or reach a certain level of power. Data were analyzed 
with EZR (version 1.37) [22]. P values < 0.05 were consid-
ered to indicate a statistically significant difference.
The immune related factors of CNB and surgical speci-
mens were compared using Spearman’s paired rank correla-
tion coefficient (Rs). To evaluate the correlation between the 
TILs, CD4 + and CD8 + lymphocytes in CNB and surgical 
specimens, Rs was calculated. Rs of < 0.4, 0.4–0.7, 0.7–0.9, 
and > 0.9 indicated poor, moderate, good, and excellent reli-
ability, respectively.
To evaluate and compare the effects of preoperative met-
formin, we defined changes in TILs, CD4 + and CD8 + lym-
phocytes exceeding 20% as positive. The Related-Samples 
Wilcoxon Signed Rank test was performed for comparisons 
of the expressions of all immune factors.
Results
Correlation of TILs, CD4 + and CD8 + T‑lymphocyte 
numbers between CNB and surgical specimens
Fifty-nine patients were evaluated as a correlation group. 
Patient characteristics are presented in Table 1. The median 
age was 65 (32–87) years. The median tumor size was 
15 mm (range 2–52). Invasive ductal carcinoma accounted 
for 56 (95%) and invasive lobular carcinoma for 3 (5%) 
cases. Histological grade was III in 22 (37%), II in 7 (12%) 
and I in 30 (51%) cases. The Ki67 index was high (over 
30%) in 22 (37%), intermediate (15–29%) in 17 (29%) and 
low (under 14%) in 20 (34%) cases. The breast cancer sub-
type was luminal A type (ER + , HER2 -, Ki67 < 15%) in 19 
(32%), luminal B type (ER + , HER2-, Ki67 > 15%) in 23 
(39%), luminal HER2 type in 4 (7%), HER2-enriched type 
in 4 (7%) and TN type in 9 (15%) cases (Table 1). The status 
of common biological markers did not differ between CNB 
and surgical specimens (Supplementary Table 1).
TILs in CNB were negative in 37 (63%), low in 18 (30%), 
intermediate in 4 (7%) and high in 0 cases. The correspond-
ing values in surgical specimens were 34 (58%), 16 (27%), 
4 (7%) and 5 (8%). The median numbers of lymphocytes 
expressing CD4 + and CD8 + were 34 and 27, respectively, 
in CNB and surgical specimens. We also evaluated 20 inter-
vals of the surgical specimen scores, yielding CD4 + num-
bers of 17 (29%: 0 to 20), 24 (41%: 21 to 40) and 18 (30%: 
over 41) for CNB and CD8 + numbers of 19 (32%), 30 (51%) 
and 10 (17%), respectively, for surgical specimens. (Sup-
plementary Table 1) We attributed this discordance to a 
difference in the numbers of lymphocytes exceeding 20% 
between the CNB and surgical specimens. The total con-
cordance rates, no difference, of the levels of CD4 + and 
CD8 + lymphocytes were 25 (43%) and 29 (49%), respec-
tively (Supplementary Table 2).
Correlation analysis showed moderate positive TILs cor-
relations between CNB and resected specimens (Rs = 0.63, 
p = 0.0000000872). We evaluated tumor size, tumor grade, 
subtype and Ki67 index results. All subgroup analyses 
showed positive correlations. (data not shown) Most notably, 
tumor size, Grade III, HER2-enriched type and a high Ki67 
Table 1  Clinicopathological characteristics of the correlation study 
group (n = 59)
Values
Age
Median (range) 65 (32–87)
Distribution—no. (%)
 > 50 13 (22)
 ≤ 50 46 (78)
Tumor size—median (range: mm) 15 (2–52)
 T1a—no. (%) 3 (5)
 T1b 15 (25)
 T1c 22 (37)
 T2 18 (31)
 T3.T4 1 (2)
Tumor grade (surgical specimen)—no. (%)
 I 30 (51)
 II 7 (12)
 III 22 (37)
Ki67 index—no. (%)
 0–14 20 (34)
 15–29 17 (29)
 30 22 (37)
Lymph node metastasis—no. (%)
 Positive 12 (20)
 Negative 47 (80)
Subtype (surgical specimen)—no. (%)
 Luminal A 19 (32)
 Luminal B (HER2 negative) 23 (39)
 Luminal B (HER2 positive) 4 (7)
 HER2-enriched type 4 (7)
 Triple negative 9 (15)
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index tended to show significant positive correlations (the Rs 
of these factors were all over 0.7). For TIL subsets, correla-
tions with CD4 + were poor (Rs = 0.224, p = 0.0875), while 
moderate correlations with CD8 + were noted (Rs = 0.42, p 
=  0.00917) (Table 2).
Distributions of and changes in TILs, CD4 + and 
CD8 + lymphocytes in CNB and surgical specimens 
from patients receiving metformin preoperatively
Seventeen patients were enrolled in the prospective met-
formin study. Patient characteristics are presented in Table 3. 
The median age was 58 (36–74). The median tumor size 
was 13 mm (2–23). Histological grade was III in six (35%), 
II in six (35%) and I in five (30%) cases. Nine patients had 
lymphatic invasion, but none had evidence of vascular inva-
sion. The Ki67 index was high (over 30) in 6 (35%), inter-
mediate (15–29) in 6 (35%) and low (under 14) in 5 (30%) 
cases. The breast cancer subtype was luminal A type (ER + , 
HER2-, Ki67 < 15%) in six (35%), luminal B type (ER + , 
HER2-, Ki67 > 15%) in five (30%), luminal HER2 type in 
one (6%) and TN type in five (30%) cases. The CNB speci-
mens obtained before metformin and the surgical specimens 
did not differ in terms of biological markers. Five patients 
(29%) were lymph node-positive. Nearly all characteris-
tics and pathological biomarkers were differed minimally 
between the metformin and correlation groups (Table 3).
Fifteen patients were able to take metformin for 2 weeks, 
as planned. Two patients experienced nausea (GradeI) 3 days 
after starting metformin, and therefore discontinued this 
medication.
The distributions of TILs, CD4 + and CD8 + lymphocytes 
are shown in Table 4. The TIL expression results before 
taking metformin were negative in 15 (89%) and low in 2 
(11%) patients, while after metformin 8 (47%) cases were 
negative, 8 (47%) had low and 1 (6%) showed intermediate 
expression. And CD4 + lymphocytes expression was that 5 
(29%) patients were over 20%, while after metformin there 
were 12 (71%). CD8 + lymphocytes expression was that 6 
(35%) were over 20%, while after metformin there were 10 
(59%) (Table 4).
We determined the percentages of TILs expressing 
CD4 + and CD8 + . We defined a change of at least 20% as 
indicating metformin efficacy. Comparison of the results 
obtained before versus after metformin showed an increase 
in seven (42%) cases, while one (6%) showed a decrease 
Table 2  Correlations between CNB and surgical specimens, com-
pared using the paired Spearman’s rank correlation coefficient (Rs), 
in the correlation study group
Spearman’s Rs P value
All patients r = 0.63 p < 0.001
Tumor size
 T1 (n = 40) r = 0.58 p < 0.001
 T2,3,4 (n = 19) r = 0.745 p < 0.001
Tumor Grade
 I (n = 30) r = 0.469 p = 0.00898
 II (n = 7) r = 0.558 p = 0.193
 III (n = 22) r = 0.789 p < 0.001
Ki67 index
 < 30% (n = 37) r = 0.431 p = 0.00772
 ≥ 30 (n = 22) r = 0.765 p < 0.001
Subtype
 Luminal A r = 0.424 p = 0.00465
 Luminal B (HER2 negative) r = 0.327 p = 0.16
 Luminal B (HER2 positive) r = 0.531 p = 0.0097
 HER2-enriched type r = 0.937 p < 0.001
 Triple negative r = 0.687 p = 0.00409
CD4 + lymphocytes r = 0.224 p = 0.0875
CD8 + lymphocytes r = 0.42 p = 0.00917
Table 3  Clinicopathological characteristics and tumor biology of the 
metformin study group (n = 17)
Values
Age
Median (range) 58 (36–74)
Distribution—no. (%)
 > 50 4 (24)
 ≤ 50 13 (76)
Tumor size—median (range: mm) 13 (2–23)
 T1a—no. (%) 4 (24)
 T1b 2 (12)
 T1c 10 (59)
 T2 1 (6)
 T3.T4 0 (0)
Tumor Grade (surgical specimen)—no. (%)
 I 5 (30)
 II 6 (35)
 III 6 (35)
Ki67 index—no. (%)
 0–14 5 (30)
 15–29 6 (35)
 30 6 (35)
Lymph node metastasis—no. (%)
 Positive 5 (29)
 Negative 12 (71)
Subtype (surgical specimen)—no. (%)
 Luminal A 6 (35)
 Luminal B (HER2 negative) 5 (30)
 Luminal B (HER2 positive) 1 (6)
 HER2-enriched type 0 (0)
 Triple negative 5 (30)
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in TILs. 9 cases (53%) had increased CD4 + , while four 
(24%) showed a decrease. Six cases (35%) had increased 
CD8 + and one (6%) showed a decrease (Supplementary 
Table 3).
But there were no significant differences in the change 
of TILs, CD4 + and CD8 + lymphocytes, comparing the 
patients increasing more than 20% or not (Table 5).
Distributions of and changes in IFNγ, IL‑2 and PD‑L1 
in CNB and surgical specimens from patients 
receiving metformin preoperatively
We judged IFNγ and IL-2 expressions by the H score. IFNγ 
expression in CNB was positive in two cases (15%) preoper-
atively, while six (35%) cases were positive after metformin 
administration. IL-2 expression in CNB was positive in one 
case (6%) preoperatively, while two (12%) were positive 
after taking metformin.
PD-L1 expression was judged as being negative (0%), low 
(1–9%) or high (≥ 10%). Thirteen (76%) cases were negative, 
two (12%) had low and two (12%) had high PD-L1 expres-
sion in CNB. The corresponding values in surgical speci-
mens were ten (59%), five (30%) and two (12%) (Table 4).
Comparisons of the CNB and surgical specimens yielded 
no statistically significant differences in the rises in the lev-
els of IFNγ (p = 0.0803), IL-2 (p = 1) and PD-L1 (p = 0.572) 
(Table 5).
Discussion
Interpreting limited samples, such as CNB, raises ques-
tions about both sampling adequacy and error. Regarding 
the points, the extent and potential effects of sample type 
and the spatial heterogeneity of tumor immune infiltrates 
have yet to be examined in sufficient detail. The clinical and 
scientific importance of assessing TILs in breast cancer has 
been highlighted by recent efforts to standardize the histo-
logic interpretation of TILs in patient samples. However, 
neither TIL heterogeneity nor the adequacy of core biopsy 
samples versus tissue sections has been fully documented 
[23]. This difference might be attributable to the limited area 
of tumor tissue biopsied, with indefinite tumor borders, in 
the CNB. However, Cha et al. reported there was less than 
5% differences between TILs of CNB and surgical speci-
men [24]. Compared with their study, there was slightly dif-
ferences of TILs between CNB and surgical specimen in 
our study, but Rs showed moderately positive correlations. 
(Rs = 0.63) Thus, we concluded that TILs in CNB specimens 
constitute a reliable indicator of the TIL values for the entire 
surgically resected breast tumor. In addition, in clinical set-
tings, sequential tumor core biopsies have become accepted 
in NAC and window-of-opportunity studies as a means of 
assessing early evidence of the therapeutic efficacy of an 
agent or a treatment strategy [25–27]. These have included 
neoadjuvant endocrine trials [28, 29] and the use of novel 
agents [27] in window-of-opportunity studies. These trials 
have identified the Ki67 index at 2 weeks as a predictor of 
relapse free survival [28] or efficacy [30] and as a prognostic 
marker for adjuvant chemotherapy [31, 32]. Therefore, it is 
important to determine whether CNB reflects the biology 
of the entire tumor.
The mechanism underlying the effects of metformin 
on the cancer remains uncertain. In chronic infectious 
diseases and cancer, CD8 + T cells specific for viral and/
or tumor antigens undergo repeated TCR stimulation due 
to the presence of persistent pathogens or cancer cells 
and gradually lose their ability to secrete IL-2, TNFα, 
Table 4  Changes of immune-related factors expression before and 
after metformin administration
Pre-metformin: 
CNB—no. (%)
Post-metformin: 
surgical—no. 
(%)
TILs
 Negative:0–10% 15 (89) 8 (47)
 Low:11–30% 2 (11) 8 (47)
 Intermediate:31–50% 0 (0) 1 (6)
 High: > 50% 0 (0) 0 (0)
CD4 + lymphocytes
 0–20% 12 (70) 5 (29)
 21–40% 3 (17) 7 (41)
 41–60% 1 (6) 4 (24)
 > 60% 1 (6) 1 (6)
CD8 + lymphocytes
 0–20% 11 (65) 7 (41)
 21–40% 6 (35) 10 (59)
 41–60% 0 (0) 0 (0)
 > 60% 0 (0) 0 (0)
IFNγ positive: H score ≥ 50 2 (15) 6 (35)
IL-2 positive: H score ≥ 50 1 (6) 2 (12)
PD-L1 positive 4 (24) 7 (41)
Table 5  Statistical analysis of the preoperative metformin influence, 
compared using the Related-Samples Wilcoxon Signed Rank test
Increasing—
no. (%)
No increas-
ing—no. (%)
P value
TILs 7 (42) 10 (58) p = 0.0545
CD4 + lymphocytes 9 (53) 8 (48) p = 0.0613
CD8 + lymphocytes 6 (35) 11 (65) p = 0.0646
IFNγ 5 (38) 8 (62) p = 0.0803
IL-2 6 (35) 11 (65) p = 1
PD-L1 3 (18) 14 (82) p = 0.572
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and IFNγ, eventually undergoing apoptotic elimination 
in a process known as immune exhaustion [33]. Eikawa 
revealed that metformin prevents apoptosis of CD8 + TILs 
and induces multifunctional CD8 + effector memory 
T-cells expressing the exhaustion marker Tim-3 in an 
in vivo murine study [7]. Furthermore, cancer immuno-
therapy (PD-1, PDL-1 antigen) has now been recognized 
as being among the most effective strategies for treating 
lung cancer and melanoma. In metastatic breast cancer, 
immunotherapy yields favorable outcomes. Immuno-
therapy efficacy may depend on TILs. If so, developing 
methods of increasing TILs may become an increasingly 
important research goal.
Since 1957, immuno-editing has been identified in a wide 
range of tumor progression forms. However, the relation-
ships between tumors and factors comprising the immune 
system remain complex and still are not fully understood. 
Yan et al. reported that TILs with CD8 + are the main effec-
tor cells in the immune response, being associated with bet-
ter disease-free survivals, but not improved overall surviv-
als. CD4 + lymphocytes are composed of both T helper and 
regulatory cells, such that their roles are highly complex. 
Furthermore, according to Mao Y et al.’s meta-analysis, 
CD4 + lymphocytes are not prognostic markers for breast 
cancer [15]. However, CD4 + data are very limited, and 
more prospective studies are needed to confirm their prog-
nostic value in breast cancer. According to these evidences, 
if metformin improves immune function and increases the 
number of TILs, CD4 + and CD8 + lymphocytes, preopera-
tive metformin administration would be expected to enhance 
chemotherapy effects. We did not identify a statistically sig-
nificant increase in TILs, CD4 + or CD8 + lymphocytes with 
preoperative metformin, but an increasing trend was noted.
These non-statistically significant results might be due 
to the metformin administration being short-term and low 
dose, to the small number of patients and to there being few 
large tumors and/or discordance among the breast cancer 
types. A previous randomized study examined the effects 
of metformin in non-DM patients. Ko et al. reported that 
patients taking 1000 mg metformin for 6 months had a sig-
nificantly greater decline in glucose, body mass index and 
HbA1c levels [34]. In our study, we took metformin for only 
2 weeks. It may not be effective on the human unless taking 
several months as this study. However, we worried that tak-
ing metformin for a longer time and delaying surgery might 
not be feasible in actual clinical settings, we decided the 
2 weeks periods from diagnosis until surgery. We consider 
that the safety of taking 1000 mg metformin in non-DM 
patients has been proved, we think that we can increase the 
internal dose of metformin (1000 mg/day). In addition, there 
are not established evaluation methods on immune factors. 
In particular, H-score is not popular because the method of 
calculation is confusing.
If taking metformin has some influences on the immune 
system, it would be possible to improve or achieve a syn-
ergistic effect on systemic therapy like chemotherapy, 
hormone and any targeting therapies. And if the effects 
of metformin on immune function require longer treat-
ment to manifest, we should be continued postoperatively 
or be combined with adjuvant therapies. Nicole et  al. 
showed that combination of metformin with PD-1 block-
ade improved intra-tumoral T-cell function and tumor 
clearance. As a result of modifications of tumor micro-
environment, there might be some possibility to release 
immunotherapy resistance [8]. At present, there are ongo-
ing clinical trials including the following: “A Phase III 
Randomized Trial of Metformin vs Placebo in Early Stage 
Breast Cancer (NCT01101438)”, “A Study of Liposomal 
Doxorubicin + Docetaxel + Trastuzumab + Metformin in 
Operable and Locally Advanced HER2 Positive Breast 
Cancer (NCT02488564)”, “Neoadjuvant Toremifene With 
Melatonin or Metformin in Locally Advanced Breast Can-
cer”, and “Metformin Plus Neoadjuvant Chemotherapy 
in Breast Cancer”. Our study did not show a statistically 
significant difference, there were some tendency that 
metformin increases or has some effects on the immune 
functions.
Conclusion
The TIL values in CNB specimens are a reliable indicator of 
the TIL status of the entire resected breast tumor.
Preoperative metformin tends to increase TILs, CD4 + , 
CD8 + lymphocytes and IFNγ, suggesting enhancement of 
immunological anti-tumor response in the patients with 
breast cancer.
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